SAMSUNG-BIOEPIS
10.9.2019 14:02:09 CEST | Business Wire | Press release
Samsung Bioepis Co., Ltd. today announced its expansion into the Brazilian biopharmaceutical market. The first product available in the country is BRENZYS™ (etanercept), a biosimilar referencing ENBREL® .i BRENZYS™ was approved by Agência Nacional de Vigilância Sanitária (ANVISA), the country’s health regulatory agency, in December 2017 for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and non-radiographic axial spondyloarthritis.
Samsung Bioepis is continuing its business expansion in multiple markets across the world, including mainland China, where the company entered into partnerships with 3SBio and C-Bridge Capital to develop and commercialize multiple biosimilar candidates from Samsung Bioepis.
BRENZYS™ is being supplied to Sistema Único de Saúde (SUS), the country’s public health system, through a Productive Development Partnership (PDP) between Samsung Bioepis and local partners, Bionovis and Bio-Manguinhos/Fiocruz.
Under the PDP, Samsung Bioepis will supply biosimilar products or product intermediaries to the local partners for sale to SUS for a period of 10 years. During this period, Samsung Bioepis will provide technology transfer to the local partners, so that manufacturing responsibilities can be gradually transferred to enable local manufacturing in Brazil. The PDP scheme was introduced by the Brazilian government in 2008, in order to expand access to medicines and support the country’s pharmaceutical industry through technology transfer from established companies in return for guaranteed purchases from SUS.
In Brazil, over 75% of patients nationwide rely on SUS for health care coverage.ii While biologics represent approximately 4% of all medicinal products acquired by SUS, they account for approximately 51% of government spending on medicinal products.iii
“We are excited to provide our high-quality biosimilars to patients across Brazil, and look forward to working with our local partners to enhance patient access to high-quality healthcare. Equally important, by sharing our scientific knowledge with our local partners, we hope to do our part in contributing to the long-term development of the Brazilian biopharmaceutical industry,” said Sang-Jin Pak, Senior Vice President and Head of Commercial Division, Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening their availability for patients and health care systems across the world.”
Samsung Bioepis’ products are now available across five continents: North America, Europe, Asia, Oceania, and Latin America. The company currently has four biosimilars approved and marketed across Europe, which include the anti-TNF trio of BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab), as well as an oncologic biosimilar, ONTRUZANT® (trastuzumab). Over 170,000 patients are currently under treatment with Samsung Bioepis’ biosimilars in Europe. In the United States, the company has one biosimilar – RENFLEXIS® (infliximab-abda) – approved and marketed. ONTRUZANT® (trastuzumab-dttb) received approval from the U.S. Food and Drug Administration (FDA) in January 2019, while ETICOVO™ (etanercept-ykro) and HADLIMA™ (adalimumab-bwwd) received FDA approval in April and July 2019, respectively.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com .
_____________________________
i
ENBREL is a registered trademark of Pfizer
ii
Jurberg C, Humphreys G. Brazil's march towards universal coverage. Bull World Health Organ
. 2010;88(9):646-7.
iii
Debiasi M, et al. Biosimilars in Brazil: The Beginning of an Era of Broader Access. Journal of Cancer Therapy
. 2017; 8:814-826.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005444/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons enters into €500 million SACE-backed term loan facility28.7.2026 13:30:00 CEST | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) announced today that it has entered into a new €500 million medium-long-term financing provided by HSBC Continental Europe (acting as Sole Coordinator and MLA), Intesa Sanpaolo S.p.A. (acting as SACE Agent and MLA), and BPER Banca Corporate & Investment Banking (acting as Structuring Advisor and MLA). The facility, which matures in March 2031, benefits from a guarantee provided by SACE, in advancement of SACE’s mission to support the international growth of Italian businesses. Together with €495 million of additional term loan A financing and a €490 million increase in commitments under Bending Spoons’ revolving credit facility, the transaction brings the aggregate amount of new and expanded facilities agreed by Bending Spoons from the beginning of the second quarter to €1.49 billion. Both the term loan A financing and the additional revolving credit facility commitments are available for general corporate purposes and acquisitions, with each of the
Promega Achieves 100% Renewable Electricity Across Global Operations28.7.2026 13:00:00 CEST | Press release
Sustainability accomplishments announced in life sciences company's 2026 Corporate Responsibility Report Promega Corporation today released its 2026 Corporate Responsibility Report, detailing significant environmental and social progress across its global operations. The report marks three milestones for the company: achievement of 100% renewable electricity across all global operations, the completion of a comprehensive value chain emissions inventory and validation of near-term emissions reduction targets by the Science Based Targets initiative (SBTi). “Our 100% renewable electricity reflects years of deliberate investment, from solar arrays on the Madison campus to renewable partnerships in the communities where we operate,” says Corey Meek, Promega Global Sustainability Manager. “Looking forward, we will continue working to strategically reduce the environmental impact of our global business.” Promega recently completed its first comprehensive greenhouse gas inventory across its gl
Lenovo Powers Esports World Cup 2026 as a Founding Partner28.7.2026 11:00:00 CEST | Press release
Lenovo™ joins EWC 2026 as a Global Partner with expanded integration across competition technology at the world’s largest esports eventLenovo Legion™ desktop PCs and monitors will equip players, broadcast operations, training facilities, and festival experiences throughout Paris this summerFans can experience the latest Legion innovations, including the Legion Pro Rollable Concept, during the seven-week competition The Esports Foundation (EF) and Lenovo today announced an expanded partnership, with Lenovo becoming a Global Partner of the Esports World Cup 2026 (EWC) and powering the world’s largest esports event with its high-performance Legion gaming devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712251027/en/ The EWC 2026 will be bringing the world’s largest esports event to Paris for the first time, welcoming more than 2,000 players, 200 esports teams and fans from over 100 countries between July 6 and August
Ten Finalists Announced for the Reply AI Film Festival, the International Competition Bringing Together Cinema and Artificial Intelligence28.7.2026 10:00:00 CEST | Press release
The jury, chaired by Gabriele Salvatores, will announce the winners in Venice on Sunday, 6 September. The Reply AI Film Festival returns for its third edition, reaffirming its role as a meeting point for cinema, creativity and artificial intelligence. The international competition created by Reply – open to creatives experimenting with new AI technologies and tools in the production of short films – has announced its ten finalists. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728146486/en/ The international competition created by Reply – open to creatives experimenting with new AI technologies and tools in the production of short films – has announced its ten finalists. The festival will take place in Veniceduring the days of the 83rd Venice International Film Festival of La Biennale di Venezia. Selected from more than 3,000 short films submitted from 76 countries, the finalist works will take centre stage at the awards
USHIO Industry & Entertainment Announces Trademark Licensing Agreement for OSRAM-Branded Professional Technical Lighting Products28.7.2026 08:30:00 CEST | Press release
Agreement ensures continuity for customers while supporting USHIO Industry & Entertainment's business strategy USHIO Industry & Entertainment (USHIO INE) today announced the signing of a trademark licensing agreement with ams OSRAM, that enables the company to continue offering designated professional technical lighting products under the trusted OSRAM product brand. The agreement marks an important milestone following USHIO's acquisition of the former OSRAM Entertainment & Industry business and reinforces the company's commitment to ensuring continuity for customers, products and long-standing partnerships worldwide. For customers, the agreement provides continuity for professional technical lighting products that have earned a strong reputation across entertainment, cinema, industrial and other specialty lighting applications. These products will continue to be supported by USHIO Industry & Entertainment's global organization, technical expertise and customer service. "The signing of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom